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To the Editor,
Measurements of baseline, suppressed or stimulated cor-
tisol concentrations are performed in the evaluation of 
several endocrine disorders such as Cushing’s syndrome 
and adrenal insufficiency. The interpretation of endo-
crine function test results is often based on historically 
determined cut-off values without taking differences in 
analytical performance of immunoassays into account 
[1]. Therefore, the use of assay dependent cut-off values 
has been advocated [2]. However, a complicating factor 
in cortisol immunoassay measurements is the binding of 
cortisol to cortisol-binding globulin (CBG), which affects 
the binding of the capturing antibody to cortisol. There-
fore, immunoassays utilize a dissociation step to free cor-
tisol from CBG prior to measurement. The displacement 
agent and concentration used have to be carefully chosen 
to allow for maximum cortisol displacement without dis-
turbing binding characteristics of the assay antibody [3]. 
Hence, elevated CBG concentrations which are gener-
ally observed during pregnancy and oral contraceptive 
pill (OCP) usage could theoretically result in incomplete 
displacement and falsely lowered total cortisol measure-
ments. Indeed, OCP usage has been associated with a neg-
ative cortisol immunoassay bias relative to cortisol LC-MS/
MS methods and a recent study has reported that most 
cortisol immunoassays show decreased recovery of corti-
sol measured in a pregnant female cohort with elevated 
CBG concentrations [4, 5]. Both synthetic and endogenous 
estrogens influence the expression of estrogen-sensitive 
hepatic proteins including CBG, thyroxin-binding globu-
lin and sex hormone-binding globulin, resulting in higher 
total hormone concentrations [6–8]. Therefore, women 
are generally advised to stop OCP usage 4–6 weeks prior 
to endocrine function tests that use cortisol as a readout 
to be able to use the generally accepted cut-off values. 
However, the increase in concentration of binding pro-
teins varies between individuals due to the level of OCP 
compliance, differences in total estrogen intake during 
the OCP-cycle and differences in OCP formulations [6, 
8]. Nevertheless, in women self-reporting to be non-OCP 
users, occasionally high baseline cortisol concentrations 
are observed, suggesting increased CBG concentrations 
due to high levels of endogenous estrogens.
To substantiate the relationship between cortisol 
quantification and CBG levels, we studied the role of 
the cortisol-CBG ratio as a possible determinant of assay 
related bias. We used serum samples from adrenocorti-
cotropic hormone (ACTH) stimulation tests (250 μg tetra-
cosactin) which consisted of a baseline sample (t = 0 min) 
and a stimulated sample (t = 60 min) from non-OCP and 
OCP users. Concerning OCP formulations, levonorgestrel- 
and desogestrel-containing formulations are the most 
prescribed in the Netherlands (70 and 10% of all OCP 
users respectively) which contain 20–30 μg ethinyl estra-
diol [9]. At stable CBG concentrations, the difference in 
observed immunoassay bias would be mainly attributable 
to the ACTH-induced production of cortisol and thus the 
increase in the cortisol-CBG ratio. Cortisol was measured 
with automated cortisol immunoassays (Siemens Immu-
lite 2000 and Roche Cortisol II) and compared to a routine 
LC-MS/MS method [10] which is not affected by binding 
protein concentration due to a protein denaturation step 
preceding cortisol quantification (LC-MS/MS inter-assay 
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variation: 7.2% [172 nmol/L]; 13.1% [861 nmol/L]). Samples 
above the limit of quantification of the immunoassays 
were omitted from the analysis as such samples require 
dilution prior to quantification. CBG was quantified using 
a radio immunoassay (DIAsource) (inter-assay variation: 
3.5% [21.1 mg/L]; 9.7% [113 mg/L]).
A control group consisting of 23 females, not using 
OCP, showed a small increase in CBG concentration during 
the ACTH-test (Δ1.9  mg/L [95%CI 0.45; 3.38], p = 0.013) 
(Figure 1A). The mean CBG concentration increased from 
47.3 to 49.2  mg/L. At baseline, a significant mean differ-
ence between the Immulite cortisol immunoassay and the 
LC-MS/MS method was observed (Δ31.8  nmol/L [95%CI 
8.6; 55.1], p = 0.009). There was no significant difference 
in cortisol concentration between the two methods in 
the stimulated samples which showed a large increase 
from baseline (LC-MS/MS method: mean Δ430.8  nmol/L 
[95%CI 362.8; 498.8], p < 0.0001). In addition, there was 
no correlation between the cortisol-CBG ratio (Figure 1B) 
and the percentage difference in cortisol concentration 
between the two methods and the observed bias between 
time points did not differ significantly (baseline mean 
bias −6.9% [95%CI −12.3; −1.57] and stimulated mean bias 
−3.9% [95%CI −8.4; 0.54], p = 0.38).
As expected, the mean CBG concentration in the OCP 
group (n = 36 females) was much higher (89.5 mg/L [95%CI 
81.3; 97.6]) compared to the control group (p < 0.0001). In 
contrast to the control group, no significant difference 
in CBG concentration between baseline and stimulated 
samples was observed (Figure 1C). However, both timed 
samples showed a significant mean difference between the 
Immulite cortisol immunoassay and the LC-MS/MS method 
(baseline Δ131  nmol/L [95%CI 93.0; 169.5] and stimulated 
Δ142  nmol/L [95%CI 88.5; 195.3]). Furthermore, the OCP 
group showed a positive correlation (r = 0.37) between the 
cortisol-CBG ratio and the percentage difference in cortisol 
concentration from the LC-MS/MS method (Figure 1D). A 
higher cortisol-CBG ratio was associated with less bias from 
the LC-MS/MS method and stimulated samples overall 
showed less bias compared to baseline samples (baseline 
mean bias −28.5% [95%CI −34.8; −22.2] and stimulated 




















































































































Figure 1: The effect of elevated CBG concentration on cortisol immunoassay bias.
(A) CBG concentration in the non-OCP group at baseline (t = 0 min) and following ACTH-stimulation (t = 60 min). (B) The LC-MS/MS cortisol-
CBG ratio plotted against the percentage difference between the Siemens Immulite cortisol immunoassay and the routine LC-MS/MS assay 
for the non-OCP group. (C) CBG concentration in the OCP group at baseline (t = 0 min) and following ACTH-stimulation (t = 60 min). (D) 
The LC-MS/MS cortisol-CBG ratio plotted against the percentage difference between the Siemens Immulite cortisol immunoassay and the 
routine LC-MS/MS assay for the OCP group. (E) The LC-MS/MS cortisol-CBG ratio plotted against the percentage difference between the 
Roche cortisol immunoassay and the routine LC-MS/MS assay for the OCP group. A p-value <0.05 is considered significant.
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Immunoassays can show variable bias due to assay 
characteristics and susceptibility to matrix effects [5, 11]. 
Therefore, we repeated the measurements of OCP samples 
using a Roche immunoassay. Both baseline and stimu-
lated samples showed a significant mean difference in 
cortisol concentration compared to the LC-MS/MS method 
(baseline Δ105.6  nmol/L [95%CI 84.0; 127.3] and stimu-
lated Δ124.9  nmol/L [95%CI 80.6; 169.2]). Again, a posi-
tive correlation (r = 0.34) between the cortisol-CBG ratio 
and the percentage difference in cortisol concentration 
from the LC-MS/MS method was observed (Figure 1E). A 
higher ratio showed less bias from the LC-MS/MS method 
and the stimulated samples showed less bias compared 
to baseline samples (baseline mean bias −23.0% [95%CI 
−27.9; −18.2] and stimulated mean bias −13.5% [95%CI 
−17.7; −9.3], p = 0.004).
In conclusion, we show that elevated CBG levels 
affect two automated cortisol immunoassays. Changes 
in the cortisol-CBG ratio affected the amount of bias 
from a routine cortisol LC-MS/MS method. This suggests 
that elevated CBG concentrations prevent effective dis-
sociation of bound cortisol in both immunoassays tested 
here. Adrenal stimulation by exogenous ACTH effectively 
increases total cortisol concentration and the cortisol-
CBG ratio resulting in a lower immunoassay bias. Through 
an increase in total cortisol concentration, the measure-
ment error derived from non-dissociated cortisol becomes 
smaller and hence reduces the bias between immuno-
assay and LC-MS/MS. The decrease in bias observed after 
stimulation will however affect the calculated value of the 
incremental cortisol response between the timed samples, 
leading to possible overestimation of the increment. Thus, 
correct measurement of cortisol in the presence of an 
elevated CBG concentration is dependent on the cortisol-
CBG ratio. As this ratio is not known a priori and requires 
measurement of CBG, efficient and correct quantification 
of cortisol under these circumstances favors the use of a 
routine cortisol LC-MS/MS method. In addition, we show 
that the CBG concentration in the OCP group is subject 
to large variation (Figure 1C) which is probably related 
to differences in exposure to synthetic estrogens and the 
use of different OCP formulations. Therefore, we question 
the feasibility of determining OCP-specific cut-off values 
for endocrine testing as synthetic estrogen exposure, OCP 
formulation and the dynamics of estrogen induced CBG 
expression during an OCP-cycle will influence the results 
of endocrine function tests.
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